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a b s t r a c t
Rotavirus nonstructural protein 4 (NSP4) is a protein with pleiotropic properties. It functions in rotavirus
morphogenesis, pathogenesis, and is the ﬁrst described viral enterotoxin. Since many bacterial toxins
function as potentmucosal adjuvants, we evaluatedwhether baculovirus-expressed recombinant simian
rotavirus SA11 NSP4 possesses adjuvant activity by co-administering NSP4 with keyhole limpet hemo-





immunization, NSP4 signiﬁcantly enhanced both systemic and mucosal immune responses to model
immunogens, as compared to the control group, in an antigen-speciﬁc manner. Both full-length and a
cleavage product of SA11 NSP4 had adjuvant activity, localizing this activity to the C-terminus of the pro-
tein. NSP4 forms fromvirulent and avirulent porcine rotavirusOSU strain, and SA11NSP4 localizedwithin
a 2/6-virus-like particle (VLP) also exhibited adjuvant effects. These studies suggest that the rotavirus




Many infectious pathogens come into contact with the host at
ucosal surfaces. Conventional parenteral vaccines are generally
neffective at elicitingmucosal immunity [1–3]. Recent efforts have
ocused on the development of mucosal vaccines in an attempt
o combat invading pathogens at the site of contact by efﬁciently
nducing both mucosal and systemic immune responses. How-
ver, one major drawback is the intrinsic low immunogenicity of
any protein antigens when administered mucosally. Therefore,
he need for mucosal adjuvants is pivotal for development of effec-
ive and safe mucosal vaccines.
The most widely studied mucosal adjuvants are the cholera
oxin (CT) from Vibrio cholerae, and its close relative, the heat-labile
nterotoxin (LT) from Escherichia coli. Aside from their function-
ng as enterotoxins, both CT and LT have been shown to function
s potent adjuvants via binding to the ganglioside GM1 receptor,
hich results in cellular activation, expression of surfacemolecules
nd cytokine production [4]. However, intranasal delivery of these
acterial enterotoxins may induce neurotoxic effects [5,6]. Mutant
orms of cholera (mCT) and heat-labile toxin (mLT), which lack tox-
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icity while retaining adjuvanticity, have been described [7]. The
development of a safe, non-toxic mucosal adjuvant that can be
delivered intranasally would be an attractive alternative to bac-
terial toxins.
The ﬁrst described viral enterotoxin is the rotavirus nonstruc-
tural protein 4 (NSP4). NSP4 is capable of inducing dose- and
age-dependent diarrhea in neonatal mice without causing histo-
logical alterations [8]. A cleavage product, NSP4(112–175), found
in the supernatant of rotavirus-infected cell cultures [9] can cause
Ca2+ mobilization in vitro and induce dose- and age-dependent
diarrhea in vivo, just like the full-length protein. Since bacterial
toxins, such as CT and LT, are well established to function as
potent mucosal adjuvants, we asked if NSP4 also possesses adju-
vant activity. In this study we tested the viral enterotoxin NSP4
from several virus strains for adjuvant activity in mice following
intranasal administration of classical model protein antigens and
evaluated the mucosal and systemic antibody responses.
2. Materials and methods
2.1. Animals
Open access under CC BY-NC-ND license.Six- to eight-week-old inbred BALB/c female mice were
obtained from Charles River Laboratories (Wilmington, MA). All
animals were housed in microisolator cages throughout the study























































vO.V. Kavanagh et al. / V
.2. Expression and puriﬁcation of recombinant NSP4
Recombinant NSP4 including the full-length and cleavage prod-
ct (112–175) from simian SA11 C13, full-length NSP4 from
irulent and attenuated porcine rotavirus strains OSU-v and OSU-a
ere puriﬁed from Spodoptera frugiperda (Sf9) insect cells infected
ith baculovirus recombinants as described previously [9,12,13].
rieﬂy, NSP4-encoding rotavirus gene 10 sequenceswere cloned in
he TOPO TA vector (Invitrogen Life Technologies, Chicago, IL) and
ubcloned into the baculovirus transfer vector pFastBAC1 (Invitro-
en). Recombinant baculoviruses expressing NSP4 were generated
s described by the manufacturer, and recombinant virus stocks
ere plaque puriﬁed. NSP4 was ﬁrst semi-puriﬁed by fast pro-
ein liquid chromatography using a quaternarymethylamine anion
xchange column pre-equilibrated with buffer (20mM Glycine-
Cl, pH 8.1). The NSP4-rich fractions were pooled and further
uriﬁed using an agarose immunoafﬁnity column ontowhich puri-
ed anti-NSP4 (114–135) rabbit IgG had been immobilized [8].
he bound NSP4 was eluted with 0.1M Tris–HCl buffer at pH 2.8.
he eluate was dialyzed against 50mMNH4HCO3, lyophilized, and
tored at 4 ◦C. Prior to use, NSP4 proteinswere reconstituted in PBS.
.3. Expression and puriﬁcation of NSP4-containing
/6-virus-like particle (VLP)
Rotavirus 2/6-virus-like particles were expressed using com-
lementary DNA sequences (cDNA) for simian rotavirus SAl1 gene
egment 2, which codes VP2, and gene segment 6, which codes VP6
ere made from mRNA and subcloned into pCRII TOPO TA vectors
Invitrogen). The rotavirus genes were inserted into a baculovirus
ransfer vector capable of co-expressing up to four different pro-
eins (see below). The plasmid, pBAC4X (Novagen, San Diego, CA),
ontains two polyhedron promoters and two p10 promoters with
he homologous promoters orientated in opposite directions, one
f each in the left-hand direction, and the others, in the right-hand
irection. Each newly inserted sequence was subsequently con-
rmed by restriction digestion and the cloned genewas sequenced
o conﬁrm its integrity.
.3.1. Insertion of VP6 into the pBAC4X baculovirus transfer
lasmid (pB4X/VP6)
The VP6 gene segment was PCR ampliﬁed from the
ull-length clone pSP65/SA11–6 using the sense primer 5′-
CTAGAGGCCGGCCTTTTAAACG (XbaI restriction site underlined)
nd the antisense primer 5′-AGGCCTGGTGAATCCTCTCAC-3′ (StuI
ite underlined). Cohesive ends were generated by digesting the
equence with XbaI and StuI and the gene was inserted into
baI/StuI linearized baculovirus transfer plasmid pBAC4X behind
he left-hand polyhedron promoter.
.3.2. Insertion of VP2 into a cloning vector (pVP2)
A truncated form of the SA11 VP2 gene lacking the protease-
ensitive region encoding amino acid residues from theN-terminus
o residue 92 (VP2) [14] was ampliﬁed using the sense primer
′-ATGGGAGGCGGAGGCGCTAACAAAACTATCC-3′ andantisense5′-
TAGGTCATATCTCCACAATGG-3′ andcloned into theTOPOTApCRII
lasmid (pVP2).
.3.3. Fusion of NSP4 to VP2 (pNSP4-2)
NSP4(112–175) was PCR-ampliﬁed using the 5′-ended primer′-CCATGGTTGACAAATTGAC-3′ (NcoI restriction site underlined)
nd 3′-ended primer 5′-GCTAGCTCCTCCTCCCATTGCTGCAGT-3′
NheI site underlined). The ampliﬁed DNA fragment was digested
ith NcoI and NheI and ligated into NcoI/NheI linearized pVP2
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2.3.4. Consruction of baculovirus transfer plasmid encoding SA11
VP6 and NSP4-VP2 (pB4X/NSP4-2/6)
The pNSP4-2 was digested with NotI and AvrII restriction
enzymes to remove the gene encoding the fusion protein NSP4-2
and inserted behind the second, right-hand, polyhedron promoter
by ligation into pB4X/VP6 linearized by NotI and SpeI restriction
enzymes.
A recombinant baculovirus encoding the three rotavirus recom-
binant proteins was generated as described by the manufacturer,
and virus stocks were plaque puriﬁed. VLPs containing the SA11
rotavirusproteinsVP6and fusionproteinNSP4-VP2 (NSP4-2/6VLP)
were puriﬁedusing CsCl2 gradients and characterized as previously
described [15]. The endotoxin level in each 2/6-VLP prepara-
tion was quantitated (<0.05U/dose) using the Limulus amebocyte
assay (Associates of Cape Cod, Inc., Woods Hole, MA). Electron
microscopy was performed on each of the VLP preparations just
prior to inoculation to conﬁrm the integrity of the VLPs.
2.4. Inoculation of animals
Groups of ﬁve BALB/c mice were used to test each antigen.
All experiments included a group of mice co-administered 10g
of the mucosal adjuvant, mutant E. coli heat-labile enterotoxin
[LT(R192G)] (mLT) as a immunostimulatory control [16]. The
animals were anaesthetized by intraperitoneal administration of
ketamine (3.75mg/mouse), xylazine (0.19mg/mouse), and acepro-
mazine (0.037mg/mouse) [10] before immunization. Two doses of
intranasal immunization of 100g of KLH or OVA alone or with
full-length NSP4 (6g) or the truncated NSP4(112–175) (10 or
20g) were carried out three weeks apart. Tetanus toxoid used for
immunization was kindly provided by Dr. Jerry McGhee (Univer-
sity of Alabama, Birmingham) or from the Statens Serum Institute
(Copenhagen, Denmark). Animals were immunized intranasally
with 10g of TT alone or co-administered with 10g of either
full-length NSP4 or NSP4 internalized in VLPs (NSP4-2/6 VLP) three
times, two weeks apart.
2.5. Sample collection
Serum and fecal samples were collected before vaccination (0
DPI) and at 14 days post second or third immunization. Blood sam-
ples were collected by tail bleed for separation of serum. Fecal
samples were collected with a fecal collection cage as previously
described [17] and processed to make 20% (w/v) suspensions in
stool diluent as described previously [11,18]. All samples were
stored at −80◦ until assayed.
2.6. Sample analysis
(i) ELISA to measure KLH- or OVA-speciﬁc serum antibody
responses. All ELISAs were performed on 96-well polyvinyl
chloride microtiter plates (Dynatech, McLean, VA). Plates
were coated with 100l of KLH or OVA (10g/ml) in
carbonate–bicarbonate buffer (pH 9.6) and incubated for 4h
at room temperature. Non-speciﬁc protein binding sites were
blocked with 5% BLOTTO. Following each step after the block,
the plates were washed three times with 0.05% Tween 20 in
PBS with an Ultrawasher Plus Platewasher (Dynatech). Serum
samples from individual animalswere seriallydiluted two-fold
down the plate in 5% BLOTTO. Samples were then incubated
for 2h at 37 ◦C. Horseradish peroxidase-conjugated goat anti-
mouse IgG antibody (Sigma) diluted 1:7500 in 2.5% BLOTTO
was then added to all wells and incubated for 1h at room
temperature. All reactionswere detected using TMBMicrowell
ELISA substrate (Kirkegaard and Perry Laboratories, Gaithers-
burg, Md.). The substrate was allowed to react for 10min








fig. 1. KLH-speciﬁc serum and fecal antibody response proﬁles of mice intranasally
eeks apart, with KLH alone, KLH+NSP4, NSP4 alone, or KLH+mLT as the immunos
y ELISA. Panel (A) shows the KLH-speciﬁc serum IgG results in Geometric Mean Tit
he ratio of nanograms of KLH-speciﬁc IgA per microgram of total IgA among variou
at room temperature, and then the reaction was stopped by
adding an equal volumeof 1MH3PO4. Optical densities (OD) at
450nmwere determinedwith a SpectraMax 190 Plate Reader
(Molecular Devices, Inc., Palatine, IL). End point titer values
were determined as the reciprocal of the highest dilution that
had an absorbance value greater than or equal to 0.1 above the
background value.
(ii) ELISA to measure KLH- and OVA-speciﬁc fecal antibody
responses. Plateswere coatedwith antigen as described above.
Puriﬁedmouse IgA standard (Sigma Chemical Co.) was diluted
in 1%BLOTTO–0.5% fetal bovine serum (FBS), added at an initial
concentration of 0.5g/ml, and serially diluted two-fold down
theplate. All plateswere incubated for4hat roomtemperature
then blocked and washed as described above. Fecal samples
(20% suspension) from individual animalswere serially diluted
ig. 2. Serumand fecal antibody proﬁles ofmice intranasally inoculatedwith SA11NSP4 an
ith model antigen alone, co-administered with full-length NSP4 or with mLT as an imm
ssayed by ELISA. Panel (A) shows the KLH-speciﬁc serum IgG and total immunoglobulin
ecal IgA responses, panel (C) shows OVA-speciﬁc serum IgG levels and panel (B) shows Olated with KLH and SA11 NSP4. Animals (n=5) were administered two times, three
atory control. Samples were collected 14 days post second inoculation and assayed
MT) and panel (B) shows the level of KLH-speciﬁc fecal IgA responses expressed as
unized groups of mice.
two-fold down the plate with 1% BLOTTO–0.5% FBS and incu-
bated for 2h at 37 ◦C to assay for KLH-speciﬁc IgA. Horseradish
peroxidase-conjugated goat anti-mouse IgA antibody (Sigma
Chemical Co.) diluted 1:10,000 in 2.5% BLOTTO–0.5% FBS was
then added to all wells and incubated for 1h at 37 ◦C. All
reactions were developed, stopped and detected as described
above. The level of KLH-speciﬁc IgA was calculated from the
linear portion of a standard curve determined as previously
described [18]. Each fecal antibody response was expressed as
the ratio of nanograms of KLH-speciﬁc IgA per microgram of
total IgA.(iii) ELISA to measure TT-speciﬁc serum and fecal antibody
responses. Plates were coated with 10g/ml of TT overnight
at room temperature. All reactions were detected, quantitated
and analyzed as described above.
d either tetanus toxoid (TT) or ovalbumin (OVA). Animals (n=5)were administered
unostimulatory control. Samples were collected 14 days post ﬁnal inoculation and
results in Geometric Mean Titers (GMT), panel (B) shows the level of KLH-speciﬁc
VA-speciﬁc IgA fecal levels among the various immunized groups of mice.
































ﬁig. 3. KLH-speciﬁc serum and fecal antibody response proﬁles of mice intranasall
leavage product NSP4(112–175) were given intranasally two times three weeks ap
g of KLH-speciﬁc IgA per microgram of total IgA (B) were evaluated in all immuniz
. Data analysis
End point titers of antigen-speciﬁc antibody responses were
etermined for each individual animal. The geometric mean titers
GMTs) were determined for each group of mice. Standard errors
ere calculated for log-transformed titers. Statistical analyses
ere performed with SPSS version 10.0 for Windows (SPSS, Inc.,
hicago, IL). Antibody titers or levels of antibodies between groups
ere compared by using the Kruskal–Wallis test followed by the
ann–Whitney U rank sum test.
. Results
.1. Adjuvant activity of full-length NSP4 from SA11
Animals immunized with 100g of KLH and either a 6 or 20g
ose of full-length NSP4 as an adjuvant. Both doses of NSP4 exhib-
teda statistically signiﬁcant (p=0.04Mann–WhitneyUTest) 6-fold
ncrease in KLH-speciﬁc serum IgG titers (GMT=72,839) com-
ared to the group of mice receiving KLH alone (GMT=11,494)
Fig. 1A) and so the lower dose was chosen for future experi-
ents. In addition, those animals also showed signiﬁcantly higher
p=0.05, Mann–Whitney U Test) (>30-fold increase) KLH-speciﬁc
ecal IgA antibody responses (GMT=2302ng/ml) compared to the
ntigen alone group (GMT=71ng/ml) (Fig. 1B). Serum IgG and fecal
gA speciﬁc antibody levels decreased approximately 20-fold and
0-fold, respectively, when mice were inoculated with KLH co-
dministered with NSP4 compared to mLT (GMT; IgG=1,447,738;
gA=74,083ng/ml).
When full-length NSP4 was given with TT (10g), it enhanced
erum TT-speciﬁc total immunoglobulin (GMT=11,143) responses
17-fold increase) to a greater extent than to those seen with KLH,
hen compared to the antigen alone group (Fig. 2A). However,
ig. 4. TT-speciﬁc serum and fecal antibody response proﬁles of mice intranasally co-a
SU-a. Animals (n=5) were given TT alone or co-administered with either of the full-len
nal inoculation and assayed by ELISA. TT-speciﬁc serum total immunoglobulins expressulated with KLH and SA11 NSP4 cleavage product. Full-length NSP4 as well as the
d KLH-speciﬁc serum IgG expressed as GMT (A) and fecal IgA expressed as ratio of
oups of animals 14 days after the second inoculation.
in contrast to the enhanced fecal antibody responses observed
when KLH was given as the antigen, there was no signiﬁcant
increase (p>0.05, Mann–Whitney U Test) of TT-speciﬁc fecal anti-
body response in the group of animals that received NSP4 and TT
as compared to TT alone (Fig. 2B).
In contrast to the observations with KLH and TT, NSP4 did
not enhance serum antibody responses to OVA (GMT=28,963)
compared to the antigen alone (GMT=15,521) group (Fig. 2C).
However, a signiﬁcantly higher level (11-fold increase; (p=0.02
Mann–WhitneyU) of OVA-speciﬁc fecal IgA (GMT=346ng/ml)was
detected when NSP4 was co-administered when compared with
the OVA alone (GMT=31ng/ml) control (Fig. 2D).
4.2. The adjuvant domain of NSP4 is located in the C-terminus of
the protein
The adjuvant activity of the cleavage product NSP4(112–175)
was tested using KLH. Similar to full-length NSP4, either 10g
or 20g of the cleavage product NSP4(112–175) enhanced KLH-
speciﬁc serum IgG (5-fold) and fecal IgA (30-fold) (Fig. 3A and B) to
levels higher than those observed in mice that received KLH alone
(p<0.05,Mann–WhitneyU). Asbothdoses inducedequivalent anti-
body titers we chose the lowest dose to perform the subsequent
experiments. These data indicate that the adjuvant domain of this
protein is located in the C-terminus of NSP4 and that 10g of the
cleavage product is optimal to elicit this effect.
4.3. An avirulent NSP4 can also function as an adjuvantTo test whether NSP4 from other rotavirus strains besides the
simian SA11 Cl3 NSP4 can also function as adjuvants, we tested the
adjuvant activity of NSP4 from both a virulent and tissue culture-
attenuated pair of porcine rotavirus strains, OSU-v and OSU-a,
dministered TT with full-length NSP4 from the rotavirus strains SA11, OSU-v and
gth NSP4 forms three times two weeks apart. Samples were collected 14 days post
ed as GMT (A) and fecal IgA in ng speciﬁc IgA per microgram total IgA (B).
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Fig. 5. Characterization of 2/6-VLP containing NSP4 and TT-speciﬁc serum and fecal antibody response proﬁles of mice intranasally co-administered TT with rotavirus 2/6
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dLP containing NSP4. To test another form of NSP4 obtained from a system other th
sed as immunogens. (A) Negative stain (1% uranyl acetate, pH 4.5) electron micr
nimals (n=5) were given TT alone or co-administered with either 2/6 VLP alone o
ost ﬁnal inoculation and assayed by ELISA TT-speciﬁc serum IgG (B) and fecal IgA
espectively. As shown in Fig. 4, both OSU-a (GMT=14,703) and
SU-v (GMT=14,703) NSP4 induced an enhanced (8-fold increase)
T-speciﬁc serum, but not fecal, antibody response compared to the
roup receiving TT antigen alone. In addition, the levels of antibody
nduced by OSU-a and OSU-v NSP4 were similar to that induced by
A11 Cl3 NSP4.
.4. NSP4 delivered by a rotavirus 2/6-VLP also has intranasal
djuvant effects
We next determined if NSP4, localized within a VLP, retained
djuvant activity. NSP4(112–175) was genetically fused to the
nner core protein VP2 and when co-expressed with VP6 in insect
ells VLPs (NSP4-2/6) were produced which were morphologically
ndistinct from 2/6 VLP (Fig. 5A). Signiﬁcantly increased (12-fold)
T-speciﬁc serum antibody was induced in the group of mice
hat received NSP4-2/6 intranasally with TT (GMT=1838) com-
ared to the TT alone group (GMT=159) (Fig. 5B). In addition,
espite the inability of the soluble NSP4 to enhance humoral
esponse against TT, NSP4 internalized within 2/6-VLPs elicited
igniﬁcantly increased fecal IgA levels (p≤0.05) compared to the
o-administered antigen (Fig. 5C). This adjuvant effect was due to
he presence of NSP4 since 2/6 VLPs given with TT did not increase
ntigen-speciﬁc antibody responses and the level of antibody was
omparable to the group receiving TT alone
. Discussion
In this study we demonstrated the mucosal adjuvant activity of
otavirus nonstructural protein NSP4 using model antigens. Full-
ength NSP4 from the SA11 rotavirus strain as well as a cleavage
roduct NSP4 (112–175) were able to function as intranasal adju-
ants and enhanced both serum and mucosal antibody responses
peciﬁc to the co-administered antigen. In addition, an attenuated
SP4 from an avirulent porcine OSU-a rotavirus as well as NSP4
elivered inside a rotavirus VLP can efﬁciently enhance antigen-
peciﬁc antibody responses. The adjuvant property of NSP4 varied
epending upon the co-administered antigen suggesting that thebaculovirus-expressed and afﬁnity-puriﬁed SA11 NSP4-containing 2/6 VLPs were
hs of NSP4-2/6 VLP produced in insect Sf9 cells. Magniﬁcation bar equals 100nm.
LP containing NSP4 three times two weeks apart. Samples were collected 14 days
re evaluated for enhanced responses compared to the antigen alone group.
outcome of adjuvanticity is affected by the nature of the antigen
tested.
In this study, porcine OSU-aNSP4 induced comparable antibody
levels to SA11 or OSU-v NSP4 when tested as adjuvants. The viru-
lent porcine NSP4 OSU-v and attenuated OSU-awere cloned from a
pair of porcine rotavirus strains. OSU-v induces severe diarrhea in
piglets and neonatalmice; however, serial passage in tissue culture
resulted in an attenuated strain, called OSU-a, with signiﬁcantly
reduced pathogenicity [19]. SA11 NSP4 and OSU-v NSP4 exoge-
nously administered to human colonic adenocarcinoma HT29 cells
induce a signiﬁcant mobilization (10-fold increase) in intracellu-
lar calcium ([Ca2+i ]) compared to OSU-a. Although further studies
will be needed to fully understand the mechanism of adjuvancity
of these proteins, the fact that all three forms of NSP4 (SA11, OSU-
v and OSU-a) possess similar adjuvant activities suggests that this
activity is independent of the diarrhea-inducing or calcium mobi-
lization abilities of these proteins. Future studies should also test
the adjuvant activity potency of NSP4 from other rotavirus strains.
The mechanism by which NSP4 exerts its adjuvant function
remains to be determined. Although the viral enterotoxin NSP4
causes diarrhea in rodents like the well-characterized bacterial
enterotoxins, LT and CT, the mechanisms of pathogenesis and host
age restrictions are different. Therefore, we anticipate that the
mechanism by which NSP4 exerts its adjuvant effect is likely to be
different from LT or CT. NSP4 does not induce detectable elevations
in intracellular cAMP (unpublished data), which has been shown
to be necessary for bacterial toxins to function as mucosal adju-
vants [20]. Another possible explanation may be due to the direct
effect NSP4 exerts on tight junctions similar to the zonula occlu-
dens toxin (ZOT) which also possesses adjuvant function [21,22].
Consequently NSP4 can decrease membrane permeability [23] and
such interruptions of the tight junction can impact mucosal per-
meability, integrity and overall function of the epithelium. Another
possible mechanism could be related to the recent discovery that
the 11 and 21 integrins are receptors for full-length SA11,
OSU-a/-vNSP4andNSP4(112–175) [24]. Ligand-binding to integrin
receptors can trigger an intracellular signal transduction pathway
resulting in transcription factor activation with subsequent down-
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role inmodulating the immune system [25–27] itwill be interest-
ng to determine if NSP4 exerts its adjuvant effect through binding
o these receptors.
Even though other mucosal adjuvants have been explored
xtensively in the past, to date, none have been approved for
uman use to be given by mucosal routes. Our studies showed
LT induced signiﬁcantly higher fecal and serum antibody titers
hen co-administered with TT and KLH model antigens, a result
hat conﬁrms previous studies with this bacterial enterotoxin or
ith CT as well as its mutants in extensive testing in various ani-
al models in combination with a variety of viral, bacterial, and
arasitic pathogens; however, safety issues still remain a concern
or these bacterial enterotoxin adjuvants [5]. Therefore, an effec-
ive, safe and practical mucosal adjuvant remains to be identiﬁed
nd characterized for the development of mucosal vaccines. Since
SP4 does not bind to GM1 receptors like CT or LT [13] it may not
ossess neurotoxic side effects. However future preclinical, safety
rials will need to be undertaken to ensure NSP4 does not enter the
rain or possess other toxicity.
Furthermore, we observed differences in adjuvant response
epending upon the nature of the co-administered antigen. The
resence of NSP4 induced a stronger immune response to the co-
dministered antigen compared to the immune response elicited
y administering the same antigen alone. This ﬁnding corre-
ates with the fact that inclusion of speciﬁc adjuvants in vaccine
reparations can modify the presentation modality of antigens
o the immune system and/or improve the induction of the
mmune response over that induced by the same antigen given
lone [28].
Virus-like particles as an alternative vaccine strategy is an
mportant area in the ﬁeld of rotavirus vaccinology. In this study
e explored the ability of NSP4 to act as an adjuvant for non-
eplicating rotavirus VLP vaccines developed in our laboratory. We
ound thatNSP4 retained its adjuvantproperties evenwhenadmin-
stered within a NSP4-2/6 VLP. The observed adjuvant effect of
SP4-2/6 was due to the presence of NSP4 since 2/6 VLPs given
ith antigen did not increase antigen-speciﬁc antibody responses.
he addition of NSP4 to 2/6 VLPs could increase the adjuvantic-
ty and immunogenicity of rotaviral vaccines andmay alleviate the
eed for co-administered adjuvants.
Future experiments will examine any adjuvant effect NSP4
xerts on the cellular arm of the immune system against co-
dministered antigen, elucidate the mechanism by which NSP4
unctions as an adjuvant and also determine if NSP4 also possesses
djuvant properties when administered by alternative routes.
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